Results 171 to 180 of about 110,182 (337)

Real-life Use of Bexarotene for T-cell Cutaneous Lymphoma Management: Efficacy and Tolerance with Low Doses. [PDF]

Acta Derm Venereol, 2022
Rouanet J, Joulie I, Lambert C, D'Incan M.   +3 more
europepmc   +1 more source

Immunology of Cutaneous T-Cell Lymphoma [PDF]

, 1991
Peter Heald, Richard L. Edelson
openalex   +1 more source

The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley   +1 more source

Granulomatous slack skin: clinical characteristics, prognosis and response to therapy. A study from the Cutaneous Lymphoma French Study Group. [PDF]

Br J Dermatol, 2022
Battesti G, Ram-Wolff C, Dobos G, Aubin F, Algros MP, Guenova E, Joly P, Courville P, Mourah S, Cayuela JM, Bouaziz JD, Moins-Teisserenc H, Battistella M, Vignon-Pennamen MD, Rivet J, Bagot M, de Masson A, Cutaneous Lymphoma French Study Group.   +17 more
europepmc   +1 more source

Cutaneous Lymphoma

Dermatologic Clinics, 2015
openaire   +2 more sources

Characterization of T-Cell Subpopulations in Skin and Peripheral Blood of Patients with Cutaneous T-Cell Lymphomas and Benign Inflammatory Dermatoses

, 1983
Rein Willemze, Claire B. De Graaff-Reitsma, J. Cnossen, W.A. van Vloten, Chris J.L.M. Meijer   +4 more
openalex   +1 more source

Differentiation between lymphadenosis benigna cutis and primary cutaneous follicular center cell lymphomas a comparative clinicopathologic study of 57 patients [PDF]

, 1990
J. U. Rijlaarsdam, Chris J.L.M. Meijer, Rein Willemze   +2 more
openalex   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Tongue and teeth hyperpigmentation in etoposide, prednisolone, vincristine, and cyclophosphamide regimen in the treatment of cutaneous lymphoma.

Indian J Pharmacol, 2023
Morabad SS, Khan ZU, Gad R, Kallur N, Madhabhavi IV, Shalavadi MH, Mangannavar CV.   +6 more
europepmc   +1 more source

Evaluation of the International Society for Cutaneous Lymphoma Algorithm for the Diagnosis of Early Mycosis Fungoides. [PDF]

Cells, 2021
Ryu HJ, Kim SI, Jang HO, Kim SH, Oh SH, Park S, Kim SK.   +6 more
europepmc   +1 more source